{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-346908","form_type":"8-K","ticker":"TRAX","cik":"0002091349","company_name":"First Tracks Biotherapeutics, Inc.","filed_at":"2026-08-12T20:19:20+00:00","discovered_at":"2026-08-12T20:20:00.184997+00:00","generated_at":"2026-08-12T20:20:07.055831+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"First Tracks Q2 net loss $33.4M, cash $168M; ANB033 Fast Track, Cohort 1 data Q4","bullets":["Q2 2026 net loss $33.4M ($0.95/share) vs $42.4M ($1.47) year-ago; R&D spend $25.6M.","FDA granted Fast Track designation for ANB033 in celiac disease; Cohort 1 (n=30) fully enrolled, data Q4 2026.","Cohort 2 expanded to up to 40 patients; top-line data expected Q1 2027; EoE Phase 1b data Q3 2027.","Cash and investments $168.0M as of June 30, 2026; runway into Q2 2028.","Planning Phase 2 trials in two additional indications in H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-346908","json":"https://secwatch.observer/filing/0001193125-26-346908.json","markdown":"https://secwatch.observer/filing/0001193125-26-346908.md","text":"https://secwatch.observer/filing/0001193125-26-346908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/0001193125-26-346908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/trax-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:20:07.055831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}